Aixial Group is a Clinical Research Organisation that collaborates with sponsors to develop therapies for oncology, cell & gene therapy, and rare diseases. It provides various clinical trial services and consulting.

Aixial Group

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Neovacs S.A.

AIXIAL GROUP | 80,861 followers on LinkedIn. Bringing reliability and expertise to clinical development | Bringing reliability and expertise to clinical development.

Aixial Group is a specialized clinical development partner with the commitment, expertise, and flexibility needed to deliver efficient clinical trials. Aixial Group provides the industry with an innovative and scalable offering, which includes: comprehensive clinical trial design and execution; functional service delivery; resources and platform.

Timothy Corbett-Clark

Christina Ehrenkrona född Brummer

Directeur Département chez AIXIAL (An Alten Company)

Stéphane THERESE

Sr. Director, Clinical & Project Management Operations

Jim Lincoln

AIXIAL GROUP

Could you imagine a world without reliable healthcare? From Medical Writing, Data & Stats to Medical & Vigilance, Clinical Operations, and QA & Regulatory affairs, our team has extensive experience in delivering demanding and innovative clinical trials. Meet the people behind the success of your clinical trials! We empower sponsors with our people and processes to enable patients to access better treatments across the globe. Learn more about our capacities: https://bit.ly/3VbRbGm Matilde Thye Kveiborg , Ashley Hunter , Valentina Zhukova-Harrill , Jules Morsch , Philip Andersen , Bastien CROUZET , Estelle de Bary , Jessica Rehheiser , Géraldine Mercier – A big thank you for your invaluable contribution! #AixialGroup #CRO #ClinicalDevelopment #Medical &Vigilance #MedicalWriting #Data &Stats #QARegulatoryAffairs #ClinicalOperation

As part of #Movember , a month dedicated to raising awareness of men's health, we are reflecting on the importance of clinical trials and early detection in the fight against prostate and testicular cancer. At #Aixial Group we are proud to contribute to the advancement of research. We have conducted 45 prostate cancer trials and 16 testicular cancer trials covering Phase I to IV worldwide. Our team of highly experienced oncology experts enables us to conduct clinical trials efficiently, on time and on budget, managing the complexities at every step. Let's continue to support men's health and raise awareness of prostate and testicular cancer during Movember. Learn more about our oncology capabilities: https://lnkd.in/d3Qvi88D #AixialGroup #Movember #ProstateCancer #TesticularCancer

Join Aixial Group at PHUSE EU Connect in Strasbourg from 10 to 13 November! Eniko Bront , our Director of Biostatistics and Statistical Programming, will take the stage on 12 November at 2:30 pm to share her insights on ‘Building for the Future: Strategies for Nurturing and Developing New Leaders’. Our team of statistical and clinical programming experts – George Allerston , Jerome Tangha , Helen Nicholson and Eniko Bront , will be at booth #9 to engage with you about the latest trends in clinical data, the industry's most pressing challenges, and how we can collaborate on innovative clinical research projects together! Contact us to find out more: info@aixial.com #AixialGroup #PhuseEUConnect #StatisticalProgramming #ClinicalResearch

The possibilities to use modified patient or donor cells to combat diseases such as cancer is a promising clinical development area. This is the essence of personalized therapies, which provide patients with the possibility of a cure through just one dose. Reach out to us now: info@aixial.com #AixialGroup #CRO #CGTs #CART #Therapies

Attending #COGEurope ? Don’t miss Laura Nichols , our Senior Director, Clinical Operations and Delivery presenting a keynote session on the benefits of early engagement with a CRO. Discover how early partnership with a CRO like #AixialGroup can enhance the success of your clinical trials. Laura Nichols will also show you how we can help you streamline regulatory strategies, optimise protocol development, and ensure that your study designs are both robust and feasible. Join us to meet our team and learn more! 📆 November 12th ⏰ 9:30 CET 📍Booth #31 #AixialGroup #CRO #COGEurope #ClinicalTrials

We will be participating at #COGEurope on 12-13 November in Amsterdam! 🌆 Our key representatives, Amit Kumar , Aaron De Mello , Anna Yanaeva , and Laura Nichols , will be at booth #31 to connect with you and discuss your current clinical studies and how we can assist you. And don't forget to catch Laura , Senior Director, Clinical Operations and Delivery presentation on Tuesday 12 November at 9:30, where she will discuss the benefits of early engagement with a CRO. See you there! For more information: info@aixial.com #AixialGroup #CRO #COGEurope #ClinicalTrials

As Pink October comes to a close, here's a glimpse of #Aixial team proudly wearing pink to show their solidarity! For the occasion, we also organised an insightful internal #webinar led by our Chief Scientific Officer, Lionel Riou França . Focusing on breast cancer, this session allowed our team to discuss this significant topic and continue raising awareness together over a shared meal. Together, we can make a difference! #AixialGroup #CRO #BreastCancerAwarenessMonth #PinkOctober #EarlyDetection

📅Save the date! This November and December, #Aixial team will attend key conferences across several cities in Europe, along with one in the US. Don't miss this opportunity to meet our experts, learn more about our expertise and discuss the latest innovations and potential collaborations together. We look forward to connecting with you at these events as we wrap up the year! EBD Group , PHUSE , PBC Group - Organisers of the COG Series , Investival Showcase , BioStock - Connecting Innovation and Capital , Medidata Solutions , Arena International Events Group #AixialGroup #Conferences #Networking

The last few months have been a busy time for our team, attending job fairs and conferences across Europe and the United States 🌍 These events have given us the opportunity to connect with industry peers, meet new talents, stay on top of the latest industry trends, and expand our global network! #AixialGroup #CRO #Networking #Conferences #Jobfairs

"It’s not enough to follow trends: you have to anticipate them, and to do that you need to bring together the best specialists" - 💬 Stéphane THERESE , Aixial Group Division Director. Our strength lies in the diversity of our talent. Through continuous training, strategic investments, and our presence at key conferences, we are anticipating changes in the industry to meet the challenges of our partners. Read his full article ➡️ https://lnkd.in/d3sZXaDX #AixialGroup #CRO #Training

Metric
Company Name	Aixial Group	Neovacs S.A.
Symbol		ALNEV
MSH ID	COM:AIXIALGROUP	COM:NEOVACS
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Clinical Research	Biotechnology
Country	FR	FR
Stage		Post-IPO Debt
Employee Count		22
Website	aixialgroup.com	neovacs.com
LinkedIn	aixialgroup	neovacs
Founders

Metric
Market Cap		52.99K
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital		4.77M

Metric
Revenue		563.41K
Revenue (LTM)
Revenue (NTM)
Gross Profit		-7.13M
EBITDA		-7.12M
Operating Income		-7.30M
Net Income		-9.24M
EPS		-0.00
Diluted EPS		-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		-9.71
Operating Profit Margin		-12.95
EBITDA Margin		-12.64
Net Profit Margin		-16.39
Return on Equity		-0.12
Return on Assets		-0.11
Return on Capital Employed		-0.14

AIXI

COM:AIXIALGROUP

Aixial Group

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		5.78
EV Multiple		-0.04

Metric
Days Sales Outstanding
Days Payables Outstanding		1.22K
Days Inventory Outstanding
Operating Cycle		11.67K
Cash Conversion Cycle		11.39K
Asset Turnover		0.01

Metric
Operating Cash Flow		-2.02M
Free Cash Flow		-2.24M
Cash Flow to Debt		-1.47
Operating Cash Flow/Sales		-3.59
Free Cash Flow Yield		-0.00

Metric
Cash & Equivalents		936.97K
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization		0.06
Debt to Assets		0.02
Current Ratio		2.32
Quick Ratio		1.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue